http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9221372-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc2a22a9271507062ad7e07974d3c58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-26 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57509 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate | 1992-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dce2144b544b249d18ea2478e4fb43c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_533e0e7c2b9ebca07d5be6f185d29060 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_146b02787393f2997191d024ee92c239 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2423cbb10920d01624a8edbc398d15e9 |
| publicationDate | 1992-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9221372-A1 |
| titleOfInvention | Crf analogs |
| abstract | Analogs of CRF, which are based upon hCRF, oCRF and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, β-endorphin, β-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels. Analogs include those having the formula (see SEQ ID NO:9): Y-Ser-Xaa2-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-Gln-Leu-Ala-Gln-Gln-Ala-Xaa32-Ser-Asn-Arg-Lys-Leu-Xaa38-Xaa39-Ile-Xaa41-NH2, wherein Y is an acyl group having 7 or fewer carbon atoms or hydrogen; Xaa2 is Glu or Gln; Xaa20 is Ala or Glu; Xaa21 is Met or Nle; Xaa22 is Ala or Thr; Xaa23 is Arg or Lys; Xaa24 is D-Ala or Ala; Xaa25 is Glu or Asp; Xaa32 is D-His or His; Xaa38 is Met, Nle or Leu; Xaa39 is Ala, Glu or Asp; Xaa41 is Ile or Ala; provided however that at least one of Xaa20 and Xaa39 is Ala and that the N-terminus may be shortened by a sequence of up to about 5 residues. One example is [Ala20]-oCRF. These analogs or their pharmaceutically acceptable salts, dispersed in an acceptable liquid or solid carrier, can be administered to humans. |
| priorityDate | 1991-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 258.